3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Conditions
Melanoma
3
Colorectal Neoplasms
2
Thyroid Neoplasms
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
EGFR-mutant Non-small Cell Lung Cancer
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Gemcitabine
115
130-nm albumin-bound paclitaxel
66
Albumin-Bound Paclitaxel
44
Fluorouracil
37
Magnetic Resonance Spectroscopy
35
Irinotecan
35
pembrolizumab
34
Taxes
33
Specimen Handling
33
Leucovorin
33
Oxaliplatin
31
Biopsy
23
Cyclophosphamide
21
Nivolumab
18
fludarabine
16
Radiosurgery
16
Cisplatin
16
Drug Therapy
15
Capecitabine
12
folfirinox
11
durvalumab
11
Radiotherapy
11
irinotecan sucrosofate
10
Ipilimumab
10
Cetuximab
10
Carboplatin
10
Blood Specimen Collection
10
olaparib
9
Standard of Care
9
dehydroftorafur
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
naporafenib
×
1 year
×
Clear all
NCT05907304
2026-02-27
SEACRAFT-1
Erasca, Inc.
Phase 1
Active not recruiting
86 enrolled